Integrin α2β1 mediates the anti-angiogenic and anti-tumor activities of angiocidin, a novel tumor-associated protein

Experimental Cell Research

Volumn 312, Issue 13, 2006, Pages 2443-2453

  Sabherwal, Yamini ^a   Rothman, Vicki L ^a   Dimitrov, Svetoslav ^a   L'Heureux, Darryl Z ^a   Marcinkiewicz, Cezary ^a   Sharma, Mahesh ^b   Tuszynski, George P ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Angiocidin; Angiogenesis; Integrins; Tumor progression

Indexed keywords

ANGIOCIDIN; COLLAGEN GEL; COLLAGEN TYPE 1; NEUTRALIZING ANTIBODY; TUMOR PROTEIN; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 2; VERY LATE ACTIVATION ANTIGEN 5; AMINO ACID; ANGIOCIDIN PROTEIN, HUMAN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; PEPTIDE; SCLEROPROTEIN; VERY LATE ACTIVATION ANTIGEN 1;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL ADHESION; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; UMBILICAL VEIN; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL STRAIN K 562; CYTOLOGY; ENDOTHELIUM CELL; GENE DELETION; METABOLISM; MOLECULAR MIMICRY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PROTEIN BINDING;

CITRUS MACROPHYLLA;

AMINO ACIDS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; CELL ADHESION; COLLAGEN TYPE I; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX PROTEINS; GENE DELETION; HUMANS; INTEGRIN ALPHA1BETA1; INTEGRIN ALPHA2BETA1; K562 CELLS; MICE; MICE, INBRED C57BL; MOLECULAR MIMICRY; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; PROTEIN BINDING; TUMOR CELLS, CULTURED;

EID: 33745856596     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2006.04.009     Document Type: Article

References (41)

1. Mercurio A.M., and Rabinovitz I. Towards a mechanistic understanding of tumor invasion-Lessons from the alpha6beta 4 integrin. Semin. Cancer Biol. 11 (2001) 129-141
2. Trikha M., Zhou Z., Timar J., Raso E., Kennel M., Emmell E., and Nakada M.T. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res. 62 (2002) 2824-2833
3. Anastassiou G., Schilling H., Djakovic S., and Bornfeld N. Expression of VLA-2, VLA-3, and alpha(v) integrin receptors in uveal melanoma: association with microvascular architecture of the tumour and prognostic value. Br. J. Ophthalmol. 84 (2000) 899-902
4. Maaser K., Wolf K., Klein C.E., Niggemann B., Zanker K.S., Brocker E.B., and Friedl P. Functional hierarchy of simultaneously expressed adhesion receptors: integrin alpha2beta1 but not CD44 mediates MV3 melanoma cell migration and matrix reorganization within three-dimensional hyaluronan-containing collagen matrices. Mol. Biol. Cell 10 (1999) 3067-3079
5. Leabu M., Uniyal S., Xie J., Xu Y.Q., Vladau C., Morris V.L., and Chan B.M. Integrin alpha2beta1 modulates EGF stimulation of Rho GTPase-dependent morphological changes in adherent human rhabdomyosarcoma RD cells. J. Cell. Physiol. 202 (2005) 754-766
6. Yang C., Zeisberg M., Lively J.C., Nyberg P., Afdhal N., and Kalluri R. Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. Cancer Res. 63 (2003) 8312-8317
7. Fishman D.A., Kearns A., Chilukuri K., Bafetti L.M., O'Toole E.A., Georgacopoulos J., Ravosa M.J., and Stack M.S. Metastatic dissemination of human ovarian epithelial carcinoma is promoted by alpha2beta1-integrin-mediated interaction with type I collagen. Invasion Metastasis 18 (1998) 15-26
8. Lochter A., Navre M., Werb Z., and Bissell M.J. alpha1 and alpha2 integrins mediate invasive activity of mouse mammary carcinoma cells through regulation of stromelysin-1 expression. Mol. Biol. Cell 10 (1999) 271-282
9. Cooper C.R., McLean L., Mucci N.R., Poncza P., and Pienta K.J. Prostate cancer cell adhesion to quiescent endothelial cells is not mediated by beta-1 integrin subunit. Anticancer Res. 20 (2000) 4159-4162
10. Zutter M.M., Sun H., and Santoro S.A. Altered integrin expression and the malignant phenotype: the contribution of multiple integrated integrin receptors. J. Mammary Gland Biol. Neoplasia 3 (1998) 191-200
11. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., and Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
12. Maeshima Y., Sudhakar A., Lively J.C., Ueki K., Kharbanda S., Kahn C.R., Sonenberg N., Hynes R.O., and Kalluri R. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 295 (2002) 140-143
13. Colorado P.C., Torre A., Kamphaus G., Maeshima Y., Hopfer H., Takahashi K., Volk R., Zamborsky E.D., Herman S., Sarkar P.K., Ericksen M.B., Dhanabal M., Simons M., Post M., Kufe D.W., Weichselbaum R.R., Sukhatme V.P., and Kalluri R. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res. 60 (2000) 2520-2526
14. Rehn M., Veikkola T., Kukk-Valdre E., Nakamura H., Ilmonen M., Lombardo C., Pihlajaniemi T., Alitalo K., and Vuori K. Interaction of endostatin with integrins implicated in angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 1024-1029
15. Furumatsu T., Yamaguchi N., Nishida K., Kawai A., Kunisada T., Namba M., Inoue H., and Ninomiya Y. Endostatin inhibits adhesion of endothelial cells to collagen I via alpha(2)beta(1) integrin, a possible cause of prevention of chondrosarcoma growth. J. Biochem. (Tokyo) 131 (2002) 619-626
16. Eble J.A. Collagen-binding integrins as pharmaceutical targets. Curr. Pharm. Des. 11 (2005) 867-880
17. Pozzi A., Moberg P.E., Miles L.A., Wagner S., Soloway P., and Gardner H.A. Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 2202-2207
18. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev., Cancer 3 (2003) 422-433
19. Marcinkiewicz C., Weinreb P.H., Calvete J.J., Kisiel D.G., Mousa S.A., Tuszynski G.P., and Lobb R.R. Obtustatin: a potent selective inhibitor of alpha1beta1 integrin in vitro and angiogenesis in vivo. Cancer Res. 63 (2003) 2020-2023
20. Sweeney S.M., DiLullo G., Slater S.J., Martinez J., Iozzo R.V., Lauer-Fields J.L., Fields G.B., and SanA ntonio J.D. Angiogenesis in collagen I requires alpha2beta1 ligation of a GFP*GER sequence and possibly p38 MAPK activation and focal adhesion disassembly. J. Biol. Chem. 278 (2003) 30516-30524
21. Bix G., Fu J., Gonzalez E.M., Macro L., Barker A., Campbell S., Zutter M.M., Santoro S.A., Kim J.K., Hook M., Reed C.C., and Iozzo R.V. Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin. J. Cell Biol. 166 (2004) 97-109
22. Tuszynski G.P., Rothman V.L., Papale M., Hamilton B.K., and Eyal J. Identification and characterization of a tumor cell receptor for CSVTCG, a thrombospondin adhesive domain. J. Cell Biol. 120 (1993) 513-521
23. Tuszynski G.P., and Nicosia R.F. Localization of thrombospondin and its cysteine-serine-valine-threonine-cysteine-glycine-specific receptor in human breast carcinoma. Lab. Invest. 70 (1994) 228-233
24. Arnoletti J.P., Albo D., Jhala N., Granick M.S., Solomon M.P., Atkinson B., Rothman V.L., and Tuszynski G.P. Computer-assisted image analysis of tumor sections for a new thrombospondin receptor. Am. J. Surg. 168 (1994) 433-436
25. Wakiyama T., Shinohara T., Shirakusa T., John A.S., and Tuszynski G.P. The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer. Histol. Histopathol. 16 (2001) 345-351
26. Zhou J., Rothman V.L., Sargiannidou I., Dimitrov S., Qiu C., Smith E., Sheffield J., Sharma M., and Tuszynski G.P. Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1. J. Cell. Biochem. 92 (2004) 125-146
27. Poon R.T., Chung K.K., Cheung S.T., Lau C.P., Tong S.W., Leung K.L., Yu W.C., Tuszynski G.P., and Fan S.T. Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin. Cancer Res. 10 (2004) 4150-4157
28. Young P., Deveraux Q., Beal R.E., Pickart C.M., and Rechsteiner M. Characterization of two polyubiquitin binding sites in the 26 S protease subunit 5a. J. Biol. Chem. 273 (1998) 5461-5467
29. Nilsson L.A., Lange S., and Lonnroth I. Induction of anti-secretory factor in mice by the nonintestinal parasite Schistosoma mansoni. J. Parasitol. 78 (1992) 1055-1058
30. Sabherwal Y., Rothman V., Albo D., and Tuszynski G. Angiocidin, an endogenous inhibitor of angiogenesis, is increased in the sera of cancer patients. Proc. Am. Assoc. Cancer Res. 45 (2004) 1143
31. Sabherwal Y., Rothman V.L., and Tuszynski G.P. Sensitive capture ELISA for measuring angiocidin in human serum: serum angiocidin levels in healthy volunteers and in prostate cancer patients. Proc. Am. Assoc. Cancer Res. 46 (2005) 743
32. Sabherwal Y., Rothman V.L., Poon R.T., and Tuszynski G.P. Clinical significance of serum angiocidin levels in hepatocellular carcinoma. Proc. Am. Assoc. Cancer Res. 46 (2005) 1319
33. Tuszynski G.P., Rothman V., Murphy A., Siegler K., Smith L., Smith S., Karczewski J., and Knudsen K.A. Thrombospondin promotes cell-substratum adhesion. Science 236 (1987) 1570-1573
34. Aida Y., and Pabst M.J. Removal of endotoxin from protein solutions by phase separation using Triton X-114. J. Immunol. 132 (1990) 191-195
35. Weidner N. Intratumoral vascularity as a prognostic factor in cancers of the urogenital tract. Eur. J. Cancer 32A (1996) 2506-2512
36. Marcinkiewicz C., Lobb R.R., Marcinkiewicz M.M., Daniel J.L., Smith J.B., Dangelmaier C., Weinreb P.H., Beacham D.A., and Niewiarowski S. Isolation and characterization of EMS16, a C-lectin type protein from Echis multisquamatus venom, a potent and selective inhibitor of the alpha2beta1 integrin. Biochemistry 39 (2000) 9859-9867
37. Chan B.M., and Hemler M.E. Multiple functional forms of the integrin VLA-2 can be derived from a single alpha 2 cDNA clone: interconversion of forms induced by an anti-beta 1 antibody. J. Cell Biol. 120 (1993) 537-543
38. Deveraux Q., Jensen C., and Rechsteiner M. Molecular cloning and expression of a 26 S protease subunit enriched in dileucine repeats. J. Biol. Chem. 270 (1995) 23726-23729
39. Johansson E., Lonnroth I., Lange S., Jonson I., Jennische E., and Lonnroth C. Molecular cloning and expression of a pituitary gland protein modulating intestinal fluid secretion. J. Biol. Chem. 270 (1995) 20615-20620
40. Marcinkiewicz C. Functional characteristic of snake venom disintegrins: potential therapeutic implication. Curr. Pharm. Des. 11 (2005) 815-827
41. Dimitrov S., Sabherwal Y., Raymond D., L'Heureux D., Lu Q., and Tuszynski G.P. The endothelial apoptotic activity of angiocidin is dependent on its polyubiquitin binding activity. Br. J. Cancer 93 (2005) 662-669